Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Rating of "Buy" by Brokerages

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) has earned an average rating of "Buy" from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $40.38.

A number of equities research analysts have issued reports on ORKA shares. BTIG Research started coverage on shares of Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Wedbush reaffirmed an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 15th. Finally, Wall Street Zen upgraded shares of Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, June 22nd.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. purchased a new position in Oruka Therapeutics in the 1st quarter worth about $2,505,000. ADAR1 Capital Management LLC purchased a new position in Oruka Therapeutics in the 1st quarter worth about $1,362,000. Braidwell LP increased its stake in Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company's stock worth $16,133,000 after buying an additional 424,750 shares during the period. OMERS ADMINISTRATION Corp grew its holdings in Oruka Therapeutics by 126.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company's stock worth $461,000 after acquiring an additional 25,100 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its holdings in Oruka Therapeutics by 47.9% during the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company's stock worth $5,595,000 after acquiring an additional 176,664 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Stock Down 3.7%

ORKA traded down $0.57 during midday trading on Tuesday, hitting $14.79. The company had a trading volume of 142,032 shares, compared to its average volume of 233,422. Oruka Therapeutics has a 52 week low of $5.49 and a 52 week high of $31.13. The company has a market capitalization of $553.74 million, a price-to-earnings ratio of -3.28 and a beta of -0.34. The stock's 50 day moving average price is $11.97 and its 200 day moving average price is $11.72.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. Research analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.